Novo Nordisk shares fall as ziltivekimab misses cardiovascular endpoint

The wire

1. 01Novo said ziltivekimab failed to reduce cardiovascular death, non-fatal heart attack or non-fatal stroke versus placebo in patients with atherosclerotic disease, chronic kidney disease and elevated inflammation; shares fell as much as 10%.
2. 02The miss removes one of Novo's few non-obesity growth candidates, Jefferies said, deepening the company's dependence on incretin commercial execution against Eli Lilly.
3. 03Overall adverse-event rates were similar and mortality unchanged, though serious infections were more common with ziltivekimab; Novo says it remains committed to cardiovascular disease.

From the source

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.